Skip to content

A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents

A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02517892
Acronym
MATCH-R
Enrollment
1500
Registered
2015-08-07
Start date
2014-12-18
Completion date
2025-03-31
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Oncogen-driven Cancer

Brief summary

This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer. This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.

Interventions

PROCEDUREBiopsy

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients diagnosed with confirmed cancer and who fulfill the following eligibility criteria will be considered eligible for this study: 1. Patient affiliated to a social security regimen 2. Patients scheduled to receive anticancer agents or currently receiving anticancer agents 3. Tumor lesion accessible to core biopsies (malignant effusions can represent an alternative) 4. Patient who is fully informed, able to comply with the protocol and who signed the informed consent. 5. Availability of initial tumor material (ideally frozen, or non-Bouin fixed paraffin embedded material) acquired before exposure to the targeted therapy Note: Patients may have received other treatments since treatment with targeted therapies including radiation or chemotherapy, before undergoing the study biopsy.

Exclusion criteria

1\. Coagulation abnormality prohibiting a biopsy

Design outcomes

Primary

MeasureTime frame
Type and frequency of molecular alterations in resistant tumors using whole exome sequencing30 days after inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026